The ASCO Post Evening News, a digital newsletter that curates daily breaking news in the world of hematology and oncology, was launched in June 2013. Here, The ASCO Post brings you the top 20 most read stories reported in Evening News over the past 5 years.
Adjuvant Paclitaxel/Trastuzumab Tolerable, Benefits Women With Stage I HER2-Positive, Node-Negative Breast Cancer
Adjuvant paclitaxel/trastuzumab may benefit women with small HER2-positive, node-negative tumors with little toxicity, according to a multicenter study presented at the 2013 San Antonio Breast Cancer Symposium. The findings demonstrated that after being treated with the combination, followed by...
No Survival Benefit of Adjuvant 5-FU–Based Chemotherapy After Neoadjuvant Radiotherapy or Chemoradiation for Resectable Rectal Cancer
As reported in The Lancet Oncology by Bosset et al, long-term results of the EORTC trial 22921 indicate that adjuvant fluorouracil-based chemotherapy after preoperative radiotherapy with or without chemotherapy does not affect disease-free survival or overall survival in patients with rectal...
IDH1-Mutant Malignant Astrocytomas May Be More Amenable to Surgical Resection and Linked to Better Prognosis
IDH1 mutation in patients with malignant astrocytomas may have the potential to be a predictive molecular biomarker to guide aggressive surgical resection, according to the results of a study reported by Beiko et al in Neuro-Oncology. Maximal surgical resection may contribute to a survival...
ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer
The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease.
PSA Bounce After Radiotherapy May Be Associated With Outcomes in Patients With Prostate Cancer
A temporary rise in prostate-specific antigen (PSA) scores after radiotherapy may have an association with outcomes in patients with prostate cancer, according to the study findings presented by Naghavi et al in the International Journal of Clinical Oncology. Experiencing a PSA bounce was...
SABCS 2014: Ovarian Suppression Added to Hormonal Therapy Reduces Risk of Recurrence in Some Premenopausal Women
Results of the large international SOFT trial present a convincing argument for the addition of ovarian function suppression to adjuvant hormonal therapy to reduce the risk of recurrence in premenopausal women with hormone receptor–positive breast cancer at high enough risk to be treated with ...
FDA Approves Nivolumab to Treat Metastatic Squamous Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration today approved the PD-1 inhibitor nivolumab (Opdivo) for the treatment of patients with metastatic squamous non–small cell lung cancer who have progressed on or after platinum-based chemotherapy. The approval was based on clinical trial results that...
Fallopian Tube Removal May Protect Premenopausal Women at High Risk for Ovarian Cancer From Some Surgical Side Effects
A study conducted by researchers at the Fox Chase Cancer Center shows removal of the fallopian tubes—while sparing the ovaries—may provide premenopausal women at high risk for ovarian cancer with a surgical option that may minimize cancer risk while also reducing some of the negative...
10-Year Results of MOSAIC Trial Show Continued Survival Benefit of Adjuvant FOLFOX4 in Stage III Colon Cancer
Ten-year results of the MOSAIC trial, reported in the Journal of Clinical Oncology by André et al, show a continued overall survival benefit with adjuvant FOLFOX4 (fluorouracil [5-FU]-leucovorin plus oxaliplatin) vs 5-FU/leucovorin in patients with stage III colon cancer and in the...
2016 Head and Neck Cancer Symposium: Most Recurrences of HPV-Positive Oropharyngeal Cancer Can Be Found Within 6 Months
For patients treated with definitive radiation therapy for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at 3 months and physical exams during the 6 months following treatment, according to research presented by...
ASCO 2016: Left- vs Right-Sided Primary Tumor Location Predicts Survival in Metastatic Colorectal Cancer
A retrospective analysis from a large, federally funded clinical trial in patients with metastatic colorectal cancer found that the location of the primary tumor within the colon predicts survival and may help inform optimal treatment selection. The study will be presented by Venook et al at the...
ASCO 2016: Adding Capecitabine Chemotherapy to Gemcitabine Extends Survival After Pancreatic Cancer Surgery
A European phase III trial showed that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs survival without increased toxicity. The study, by Neoptelemos et al, was featured in a press briefing today and presented at the 2016 ASCO Annual Meeting.
ASCO 2016: Atezolizumab Benefits Patients With Advanced Bladder Cancer
The anti–PD-L1 immunotherapy atezolizumab is effective in patients with previously untreated advanced bladder cancer who are not eligible for the standard treatment with cisplatin. According to a nonrandomized phase II trial by Balar et al, atezolizumab shrank tumors in about a quarter of...
2017 GI Cancers Symposium: Nivolumab Demonstrated Efficacy and Improved Survival in Patients With Previously Treated Advanced Gastric Cancer
Results of the ONO-4538-12 trial demonstrated that nivolumab significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current standard-of-care treatments, according to an abstract...
RECIL 2017: New Response Evaluation Criteria in Lymphoma Clinical Trials
New criteria for evaluating response in lymphoma clinical trials—RECIL 2017—have been developed by an International Working Group with the aim of harmonizing criteria with the Response Evaluation Criteria in Solid Tumors. The new criteria were reported by Younes et al in Annals of...
ASCO 2017: STAMPEDE Trial: Adding Abiraterone to Standard Treatment Improves Survival in Advanced Prostate Cancer
The STAMPEDE clinical trial of nearly 2,000 men shows that adding abiraterone acetate to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone vs 83% with standard therapy...
ASCO 2017: LATITUDE Trial: Addition of Abiraterone to Standard Hormonal Therapy Improves Outcomes in Newly Diagnosed Metastatic Prostate Cancer
Adding abiraterone acetate plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In the phase III LATITUDE trial of 1,200 men presented by Fizazi et al today, abiraterone also more than doubled the median...
ASCO 2017: The APHINITY Trial: Adding a Second HER2 Blocker May Lower Chance of Invasive Breast Cancer for Some Women
A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests the addition of a second HER2-targeted medicine, pertuzumab, to standard-of-care trastuzumab after surgery may improve outcomes, although the benefit is modest. The study was presented by von Minckwitz et al today.
ESMO 2017: PACIFIC Trial: Durvalumab Improves Progression-Free Survival in Stage III Lung Cancer
Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage III lung cancer, according to late-breaking results from the phase III PACIFIC trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress and published by Antonia et al in...
ASTRO 2017: GOG-249 Confirms Adjuvant Pelvic Radiation as Standard of Care for High-Risk, Early-Stage Endometrial Cancer
In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I–II high-risk endometrial cancer were not superior following adjuvant vaginal cuff brachytherapy plus chemotherapy when compared with...
